JAK2 V617F mouse liver function analysis provides a comprehensive evaluation of hepatic injury, extramedullary hematopoiesis, and hepatobiliary function in murine models of myeloproliferative neoplasms. This technical article describes the sample types, testing items, analytical methods, and research applications involved in assessing liver function in JAK2 V617F mutant mice. The guide supports researchers and preclinical study sponsors in designing robust hepatic endpoints for disease characterization and JAK inhibitor safety evaluation.
Technical Overview
The JAK2 V617F mutation is a somatic gain-of-function substitution in which valine at position 617 of the Janus kinase 2 pseudokinase (JH2) domain is replaced by phenylalanine. This mutation abrogates the autoinhibitory function of the JH2 domain, resulting in constitutive JAK2 kinase activity and hypersensitive signaling through the erythropoietin, thrombopoietin, and G-CSF receptors. JAK2 V617F is present in approximately 95% of patients with polycythemia vera (PV) and in 50–60% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF), collectively classified as myeloproliferative neoplasms (MPNs).
Transgenic and knock-in mouse models expressing JAK2 V617F, including hematopoietic-specific and inducible conditional systems, faithfully recapitulate human MPN phenotypes such as elevated hematocrit, splenomegaly, myeloid expansion, and progressive myelofibrosis. In these models, the liver is a critical target organ for analysis for several reasons. First, the liver is a major site of extramedullary hematopoiesis (EMH), where clusters of megakaryocytes and myeloid progenitors infiltrate the sinusoids and portal tracts. Second, hepatic involvement contributes to portal hypertension, sinusoidal congestion, and fibrotic remodeling observed in advanced disease. Third, JAK2 inhibitors used to treat MPNs, including ruxolitinib, fedratinib, and pacritinib, carry a risk of hepatotoxicity that must be characterized preclinically. Integrated liver function analysis therefore combines serum biochemistry, quantitative histopathology, immunophenotyping, and molecular assays to deliver a multidimensional assessment of hepatic status in JAK2 V617F mice.
Testing Samples
Serum Samples
Serum is the primary matrix for the hepatic biochemistry panel. Blood is collected from JAK2 V617F mice and matched wild-type controls via submandibular vein puncture, retro-orbital sampling under anesthesia, or terminal cardiac puncture. After clotting at room temperature, samples are centrifuged at 3,000–4,000 × g for 10–15 minutes, and the clarified serum is aliquoted to avoid freeze–thaw cycles. Serum is stored at −80°C until analysis. A typical collection volume of 150–300 µL per mouse is sufficient to complete the full hepatic panel, with terminal collections providing the largest yield.
Plasma Samples
Plasma collected in EDTA, heparin, or sodium citrate tubes is used for complementary assays such as coagulation parameters, inflammatory cytokine quantification, and bile acid profiling. Anticoagulant choice should be aligned with the downstream assay, as citrate dilution and heparin interference can affect certain enzymatic readouts. Plasma is separated by centrifugation within 30 minutes of collection and stored frozen in single-use aliquots.
Liver Tissue Specimens
Liver tissue is harvested at necropsy following a standardized sampling plan covering the left, median, and right lateral lobes to account for lobe-specific variability in EMH burden. Tissue is divided for parallel processing: fixation in 10% neutral buffered formalin for paraffin embedding and histology, snap-freezing in liquid nitrogen for RNA and protein extraction, and optimal cutting temperature (OCT) embedding for cryosectioning and fluorescence applications. Body weight, absolute liver weight, and liver-to-body-weight ratio are recorded at collection as macroscopic indices of hepatic involvement.
Whole Blood and Bone Marrow
Although not hepatic matrices per se, matched complete blood counts and bone marrow cytology/histology provide essential disease-stage context, because hematocrit, leukocyte counts, and marrow fibrosis strongly correlate with the degree of hepatic extramedullary hematopoiesis. Integrated interpretation of these paired specimens substantially strengthens the conclusions of the liver function analysis.
Testing Items
Hepatic Injury Enzyme Panel
- Alanine aminotransferase (ALT): the most liver-specific indicator of hepatocellular injury in mice.
- Aspartate aminotransferase (AST): reflects hepatocellular damage with contributions from muscle and hematopoietic cells.
- Alkaline phosphatase (ALP): marker of cholestatic and biliary injury.
- Gamma-glutamyl transferase (GGT): supplementary biliary enzyme, interpret with strain-specific reference ranges.
Bilirubin and Bile Acid Metabolism
- Total bilirubin (TBIL) and direct bilirubin (DBIL) to evaluate hepatobiliary excretory function.
- Indirect bilirubin, calculated from TBIL minus DBIL, to distinguish hemolysis-associated elevations from true hepatic dysfunction, a critical distinction given the high red cell turnover in JAK2 V617F disease.
- Total bile acids (TBA) as a sensitive, integrated functional readout of hepatic uptake, conjugation, and biliary excretion.
Hepatic Synthetic Function
- Albumin (ALB) and total protein (TP) to assess protein-synthetic capacity.
- Albumin-to-globulin (A/G) ratio, which shifts with chronic inflammation and myeloproliferative activation.
- Urea and glucose as supportive metabolic parameters affected by advanced hepatic dysfunction.
Quantitative Histopathology
- Hematoxylin and eosin (H&E) staining for hepatocyte morphology, sinusoidal dilation, necrosis, inflammatory infiltrates, and EMH foci.
- Reticulin fiber staining to evaluate sinusoidal and portal fibrosis grading.
- Masson's trichrome staining for collagen deposition and bridging fibrosis.
- Prussian blue staining for hepatic iron loading associated with dysregulated erythropoiesis and repeated phlebotomy-like stress.
- Semi-quantitative scoring of EMH burden, megakaryocyte clustering, and portal tract expansion by a veterinary pathologist.
Immunohistochemistry and Immunofluorescence
- F4/80 or CD68 for macrophage (Kupffer cell) activation and inflammatory infiltration.
- Ly6G for neutrophil recruitment.
- CD41/CD42b or von Willebrand factor to identify megakaryocytes and document EMH composition.
- Alpha-smooth muscle actin (α-SMA) for hepatic stellate cell activation.
- Collagen I and collagen III for matrix deposition mapping.
- Phospho-STAT3 (Tyr705) and phospho-STAT5 (Tyr694) to confirm target pathway engagement and JAK2 signaling activity in hepatic and infiltrating hematopoietic cells.
Molecular and Cytokine Biomarkers
- RT-qPCR panels for hepatic inflammatory mediators (Il6, Tnf, Il1b) and profibrotic mediators (Tgfb1, Pdgfb).
- Fibrosis-related gene expression including Col1a1, Col3a1, Acta2, Timp1, and Mmp2/Mmp9.
- ELISA or multiplex assays for circulating cytokines such as IL-6 and TNF-α.
- Western blot confirmation of pJAK2/pSTAT signaling and fibrosis-associated protein expression in liver lysates.
Testing Methods
Serum and plasma biochemistry is performed on fully automated clinical chemistry analyzers using International Federation of Clinical Chemistry (IFCC)-aligned reagent systems and species-appropriate calibrators. Each analytical run incorporates two levels of quality control materials with Westgard rule acceptance criteria, and results are reported with assay-specific reference intervals established for the background strain (typically C57BL/6). Instruments are qualified daily before sample analysis, and hemolyzed or lipemic specimens are flagged because free hemoglobin and elevated bilirubin interfere with several enzymatic reactions.
For histology, formalin-fixed liver lobes are trimmed according to standardized coronal planes, processed through graded alcohols, paraffin-embedded, and sectioned at 4–5 µm. Stained slides are digitized by whole-slide scanning, enabling quantitative image analysis of EMH area fraction, reticulin fiber density, and collagen-positive area in addition to conventional pathologist scoring using predefined, blinded semi-quantitative scales. Immunohistochemistry is performed on automated platforms with antigen retrieval optimization, isotype and negative controls, and positive control tissues, with signal quantification expressed as positive area percentage or integrated optical density.
Molecular testing proceeds from snap-frozen tissue homogenized under RNase-free conditions, followed by total RNA extraction, purity and integrity verification (A260/280 ratios and RIN assessment), reverse transcription, and SYBR- or probe-based qPCR. Relative expression is calculated by the ΔΔCt method normalized to validated housekeeping genes such as Gapdh, Hprt1, and Rpl13a. All group comparisons are powered by appropriate biological replication, analyzed with suitable statistical tests (ANOVA with post-hoc corrections or non-parametric equivalents), and reported with effect sizes and confidence intervals.
Applications
Liver function analysis in JAK2 V617F mice supports a broad range of translational research and preclinical development objectives, including:
- Phenotypic characterization of newly generated or newly acquired JAK2 V617F transgenic, knock-in, and conditional mouse models at defined disease stages.
- Longitudinal monitoring of hepatic disease progression, including the development of extramedullary hematopoiesis, portal fibrosis, and iron overload.
- Preclinical efficacy and safety evaluation of JAK2 inhibitors, combination therapies, and novel MPN drug candidates, with explicit detection of drug-induced hepatotoxicity.
- Mechanistic studies of hepatic inflammation, Kupffer cell activation, stellate cell fibrogenesis, and portal hypertension in myelofibrosis.
- Comparative studies interrogating modifier genes, therapeutic dosing schedules, or dietary and environmental factors that modulate hepatic manifestations of MPN.
- Biomarker discovery linking serum hepatic parameters to histological and molecular endpoints for future translational use in human MPN trials.
- Regulatory-enabling toxicology packages in which JAK2 V617F mice serve as disease-relevant safety models.
FAQ
Why is the liver specifically analyzed in JAK2 V617F mice?
The liver is a principal site of extramedullary hematopoiesis in MPN, and hepatic involvement—sinusoidal infiltration, megakaryocyte clustering, fibrosis, and iron loading—mirrors clinical findings in patients. In addition, JAK2-directed therapies can produce hepatotoxicity, so hepatic endpoints are essential for both disease phenotyping and drug safety assessment in this model.
What blood volume is required, and can sampling be performed serially?
A full hepatic biochemistry panel typically requires 100–150 µL of serum. Serial sampling via submandibular or saphenous puncture is feasible when cumulative volumes adhere to animal welfare limits (generally no more than 10% of circulating volume per draw with appropriate recovery intervals). Terminal cardiac puncture provides the highest yield for comprehensive baseline and endpoint panels.
How can elevated bilirubin be correctly interpreted in this model?
Because JAK2 V617F mice exhibit increased red cell mass and turnover, indirect bilirubin may rise from hemolysis rather than hepatic failure. Fractionating bilirubin into direct and indirect components, combined with bile acid measurement and histology, distinguishes true hepatobiliary dysfunction from hematopoietic-driven hyperbilirubinemia.
How is extramedullary hematopoiesis quantified in the liver?
EMH is quantified by combining immunohistochemistry for megakaryocytic and myeloid markers with digital image analysis of positive staining area, alongside blinded pathologist scoring of H&E sections. Reporting both morphological scores and quantitative image metrics ensures reproducibility across studies and laboratories.
Can liver function analysis be combined with hematological and splenic endpoints?
Yes, and this is strongly recommended. A standard integrated workflow pairs hepatic serum chemistry and histology with complete blood counts, spleen weight and histology, bone marrow fibrosis grading, and JAK–STAT signaling readouts, producing a coherent multi-organ dataset for interpreting disease severity and therapeutic response.
What is the typical turnaround time for a complete analysis?
Serum biochemistry results are usually available within 3–5 business days of sample receipt. Histology with digital quantification typically requires 10–15 business days, and molecular assays including qPCR and Western blotting add approximately 2–3 weeks depending on panel scope. Expedited timelines can be arranged for time-sensitive preclinical programs.